Weller, J., Waha, A., Schneider, M., Seidel, C., Steinbach, J., Hau, P., Schlegel, U., Tonn, J., Grauer, O., Sabel, M., Krex, D., Schnell, O., Ringel, F., Tabatabai, G., Goldbrunner, R., Radbruch, A., Schuss, P., Güresir, E., Vatter, H., Glas, M., Schmid, M., Schäfer, N., Tzaridis, T., Giordano, F., Zeyen, T., Schaub, C., Németh, R., Pietsch, T., & Herrlinger, U. (2021). bIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. Neuro-oncology, 23, vi11. http://access.bl.uk/ark:/81055/vdc_100146089652.0x00000f